Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, ...

RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, ...

Robert F. Kennedy Jr. is openly vowing to make money off vaccine lawsuits if confirmed as the next HHS secretary.

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

and AbbVie stock (up 15%), Merck’s stock performance has been muted. This is attributed to declining sales of its blockbuster HPV vaccine – Gardasil – and an increased competition for some ...

The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.

The vaccine was previously approved ... over 50 million women in China from certain HPV-related cancers and diseases since its first approval, Merck’s president of Human Health International ...

Merck & Co has entered into a worldwide licensing ... If successful, the programme could be somewhat analogous to its work on blockbuster HPV vaccine Gardasil, targeting a virus that generally ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

Merck's current discounted valuation ... We're proud of the role that GARDASIL is playing in helping prevent certain HPV-related cancers. There's a wide range of long-term growth opportunities ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa’s other long-term stock picks. Prem Watsa is a Canadian billionaire, entrepreneur ...